Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Shares Gap Up – What’s Next?

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) shares gapped up before the market opened on Wednesday . The stock had previously closed at $11.34, but opened at $11.97. Bayer Aktiengesellschaft shares last traded at $11.96, with a volume of 152,149 shares changing hands.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on BAYRY. Zacks Research lowered shares of Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 3rd. Barclays upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 6th. Morgan Stanley upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, December 3rd. Finally, JPMorgan Chase & Co. upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a report on Monday, December 8th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Price Performance

The firm has a market capitalization of $47.51 billion, a P/E ratio of -143.87, a P/E/G ratio of 5.97 and a beta of 0.66. The stock’s fifty day simple moving average is $9.88 and its 200 day simple moving average is $8.65. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.14 and a quick ratio of 0.71.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.